We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)
Read MoreHide Full Article
Endo International plc announced that it has begun restructuring its corporate and branded pharmaceutical R&D functions in Malvern, PA and Chestnut Ridge, NY.
Shares of Endo have underperformed the Zacks classified Medical-Drugs industry in the past one year. Specifically, the stock plunged 79.4% during this period in comparison to a decline of 10.6% for the industry.
The initiative aims to better align the corporate and branded pharmaceutical R&D functions in size and scope with the recently restructured generics and branded pharmaceutical business units in the U.S.
These initiatives are expected to provide greater efficiencies and corresponding cost savings.
These restructuring actions are likely to reduce the company’s headcount by approximately 90 full-time positions and result in pre-tax cost savings of $40 million to $50 million on an annual run rate basis by the fourth quarter of 2017.
We remind investors that Endo completed the integration, product portfolio rationalization and restructuring of its generics business segment in 2016. Thereafter, Endo introduced a unified operating model that streamlined its global supply chain organization to boost its Branded and Generics businesses. The company has eliminated its pain field sales force in the branded segment in the U.S.
We note that the company’s generic segment is under pressure given the challenging competitive landscape and pricing pressures. Consequently, Endo expects to invest a portion of these cost savings in the company's core product franchises and new product development programs for both the branded and generics business segments.
Endo currently carries a Zacks Rank #5 (Strong Sell). Shares are under tremendous pressure due to concerns related to the ongoing investigations and the present focus on drug pricing. Concerns relating to pricing are expected to remain a major overhang on the company’s shares.
Some better-ranked stocks in the health care sector include Sucampo Pharmaceuticals , Anika Therapeutics (ANIK - Free Report) and Sunesis Pharmaceuticals . While Sucampo and Sunesis sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sunesis’ loss estimates narrowed 5.06% and 8.80% for 2016 and 2017, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.1%. Its share price was up 37.2% in the past one year.
Sucampo’s earnings estimates were stable at $1.22 for 2016 but have increased from $1.58 to $1.74 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.5%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
(We are reissuing this article to correct a mistake. The original article, issued Friday, January 27, 2017, should no longer be relied upon.)
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)
Endo International plc announced that it has begun restructuring its corporate and branded pharmaceutical R&D functions in Malvern, PA and Chestnut Ridge, NY.
Shares of Endo have underperformed the Zacks classified Medical-Drugs industry in the past one year. Specifically, the stock plunged 79.4% during this period in comparison to a decline of 10.6% for the industry.
The initiative aims to better align the corporate and branded pharmaceutical R&D functions in size and scope with the recently restructured generics and branded pharmaceutical business units in the U.S.
These initiatives are expected to provide greater efficiencies and corresponding cost savings.
These restructuring actions are likely to reduce the company’s headcount by approximately 90 full-time positions and result in pre-tax cost savings of $40 million to $50 million on an annual run rate basis by the fourth quarter of 2017.
We remind investors that Endo completed the integration, product portfolio rationalization and restructuring of its generics business segment in 2016. Thereafter, Endo introduced a unified operating model that streamlined its global supply chain organization to boost its Branded and Generics businesses. The company has eliminated its pain field sales force in the branded segment in the U.S.
We note that the company’s generic segment is under pressure given the challenging competitive landscape and pricing pressures. Consequently, Endo expects to invest a portion of these cost savings in the company's core product franchises and new product development programs for both the branded and generics business segments.
Endo currently carries a Zacks Rank #5 (Strong Sell). Shares are under tremendous pressure due to concerns related to the ongoing investigations and the present focus on drug pricing. Concerns relating to pricing are expected to remain a major overhang on the company’s shares.
Endo International PLC Price and Consensus
Endo International PLC Price and Consensus | Endo International PLC Quote
Key Picks
Some better-ranked stocks in the health care sector include Sucampo Pharmaceuticals , Anika Therapeutics (ANIK - Free Report) and Sunesis Pharmaceuticals . While Sucampo and Sunesis sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sunesis’ loss estimates narrowed 5.06% and 8.80% for 2016 and 2017, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.1%. Its share price was up 37.2% in the past one year.
Sucampo’s earnings estimates were stable at $1.22 for 2016 but have increased from $1.58 to $1.74 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.5%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
(We are reissuing this article to correct a mistake. The original article, issued Friday, January 27, 2017, should no longer be relied upon.)